STAGE IVA BLADDER CANCER AJCC V8
Clinical trials for STAGE IVA BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Personalized cancer fight: matching drugs to your Tumor's genetic fingerprint
Disease control OngoingThis study is testing whether specific genetic markers in a patient's tumor can predict if they will respond well to immunotherapy drugs. It is for people with advanced bladder cancer that has spread and has stopped responding to standard chemotherapy. Participants receive two im…
Matched conditions: STAGE IVA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 18:41 UTC
-
New drug combo tested for aggressive bladder and prostate cancers
Disease control OngoingThis early-stage trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy works better for treating advanced small cell or neuroendocrine cancers of the bladder, urethra, or prostate. The study will enroll about 15 participants with cancer tha…
Matched conditions: STAGE IVA BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Targeted drug combo tested to fight tough bladder cancer
Disease control TerminatedThis study aimed to see if a targeted pill (erdafitinib) alone or combined with an immunotherapy drug (atezolizumab) could shrink aggressive bladder tumors before surgery. It was for patients whose cancer had grown into the muscle wall of the bladder and who could not receive the…
Matched conditions: STAGE IVA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC